Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis

Clinical Immunology

Volumn 116, Issue 2, 2005, Pages 101-107

  Garfield, Bruce E ^a   Krahl, Troy ^b   Appel, Stacia ^b   Cooper, Sheldon M ^a   Rincón, Mercedes ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Infliximab; p38 MAP kinase; Rheumatoid arthritis; TNF

Indexed keywords

CD4 ANTIGEN; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; MACROPHAGES; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21344475123     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2005.04.010     Document Type: Article

References (32)

1. M. Feldmann, F.M. Brennan, B.M. Foxwell, and R.N. Maini The role of TNF alpha and IL-1 in rheumatoid arthritis Curr. Dir. Autoimmun. 3 2001 188 199
2. B.B. Aggarwal, S. Shishodia, K. Ashikawa, and A.C. Bharti The role of TNF and its family members in inflammation and cancer: lessons from gene deletion Curr. Drug Targets Inflamm. Allergy 1 2002 327 341
3. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, C.G. Jackson, M. Lange, and D.J. Burge A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 1999 253 259
4. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible, and M. Feldmann Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552 1563
5. M. Feldmann, and R.N. Maini Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19 2001 163 196
6. S.J. Baker, and E.P. Reddy Modulation of life and death by the TNF receptor superfamily Oncogene 17 1998 3261 3270
7. P.W. Dempsey, S.E. Doyle, J.Q. He, and G. Cheng The signaling adaptors and pathways activated by TNF superfamily Cytokine Growth Factor Rev. 14 2003 193 209
8. B.B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword Nat. Rev., Immunol. 3 2003 745 756
9. H. Wajant, K. Pfizenmaier, and P. Scheurich Tumor necrosis factor signaling Cell Death Differ. 10 2003 45 65
10. J. Raingeaud, S. Gupta, J. Roger, M. Dickens, J. Han, R.J. Ulevitch, and R.J. Davis Pro-inflammatory cytokines and environmental stress cause p38 MAP kinase activation by dual phosphorylation on tyrosine and threonine J. Biol. Chem. 270 1995 7420 7426
11. T.H. Lee, Q. Huang, S. Oikemus, J. Shank, J.J. Ventura, N. Cusson, R.R. Vaillancourt, B. Su, R.J. Davis, and M.A. Kelliher The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase Mol. Cell. Biol. 23 2003 8377 8385
12. D. Brancho, N. Tanaka, A. Jaeschke, J.J. Ventura, N. Kelkar, Y. Tanaka, M. Kyuuma, T. Takeshita, R.A. Flavell, and R.J. Davis Mechanism of p38 MAP kinase activation in vivo Genes Dev. 17 2003 1969 1978
13. J.M. Kyriakis Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family Gene Expression 7 1999 217 231
14. S. Kumar, J. Boehm, and J.C. Lee p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases Nat. Rev., Drug Discov. 2 2003 717 726
15. C. Pargellis, and J. Regan Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis Curr. Opin. Investig. Drugs 4 2003 566 571
16. A.M. Badger, D.E. Griswold, R. Kapadia, S. Blake, B.A. Swift, S.J. Hoffman, G.B. Stroup, E. Webb, D.J. Rieman, M. Gowen, J.C. Boehm, J.L. Adams, and J.C. Lee Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis Arthritis Rheum. 43 2000 175 183
17. J.C. Lee, T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Gree, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, J.E. Strickler, M.M. McLaughlin, I.R. Siemens, S.M. Fisher, G.P. Livi, J.R. White, J.L. Adams, and P.R. Young A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 372 1994 739 746
18. M. Rincón, H. Enslen, J. Raingeaud, M. Recht, T. Zapton, M.S.-S. Su, L.A. Penix, R.J. Davis, and R.A. Flavell Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway EMBO J. 17 1998 2817 2829
19. P. Miossec, and W. van den Berg Th1/Th2 cytokine balance in arthritis Arthritis Rheum. 40 1997 2105 2115
20. S. Diehl, J. Anguita, A. Hoffmeyer, T. Zapton, J.N. Ihle, E. Fikrig, and M. Rincon Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1 Immunity 13 2000 805 815
21. S. Diehl, C.W. Chow, L. Weiss, A. Palmetshofer, T. Twardzik, L. Rounds, E. Serfling, R.J. Davis, J. Anguita, and M. Rincon Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation J. Exp. Med. 196 2002 39 49
22. B. Dérijard, J. Rainjeaud, T. Barret, I.-H. Wu, J. Han, R.J. Ulevitch, and R.J. Davis Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms Science 267 1995 683 685
23. J. Han, J.-D. Lee, Y. Jiang, Z. Li, L. Feng, and R.J. Ulevitch Characterization of the structure and function of a novel MAP kinases kinases (MKK6) J. Biol. Chem. 271 1996 2886 2891
24. T. Moriguchi, N. Kuroyanigi, K. Yamaguchi, Y. Gotoh, K. Irie, T. Kano, K. Shirakabe, Y. Muro, H. Shibuya, K. Matsumoto, B. Nishida, and M. Hagiwara A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3 J. Biol. Chem. 271 1996 13675 13679
25. D. Conze, J. Lumsden, H. Enslen, R.J. Davis, G. Le Gros, and M. Rincon Activation of p38 MAP kinase in T cells facilitates the immune response to the influenza virus Mol. Immunol. 37 2000 503 513
26. F.M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 1989 244 247
27. T.J. Smeets, M.C. Kraan, M.E. van Loon, and P.P. Tak Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue Arthritis Rheum. 48 2003 2155 2162
28. G.H. Waetzig, D. Seegert, P. Rosenstiel, S. Nikolaus, and S. Schreiber p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease J. Immunol. 168 2002 5342 5351
29. A.M. Badger, J.N. Bradbeer, B. Votta, J.C. Lee, J.L. Adams, and D.E. Griswold Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function J. Pharmacol. Exp. Ther. 279 1996 1453 1461
30. D.E. Griswold, L.M. Hillegass, P.C. Neunier, M.J. DiMartino, and N. Hanna Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis Arthritis Rheumatol. 31 1988 1406 1412
31. J.X. Zou, J. Braun, and J. Sieper Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment Clin. Exp. Rheumatol. 20 2002 S34 S37
32. + T cells in the peripheral blood of patients with rheumatoid arthritis Arthritis Rheum. 42 1999 2166 2173